APOA1 and Alzheimer disease: Encouraging results from animal models indicate that elevating ApoA-I levels can significantly reduce amyloid burden and inflammatory markers in the CNS [140], reinforcing the translational potential of ApoA-I-targeted therapies in the fight against AD.